Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Catalent Pharma Solutions remained stagnant in its fiscal second quarter, as global currency fluctuations undid baseline growth in its banner businesses.
Contract drugmaker Recipharm is promising to spend $45 million (€40 million) over the next three years to improve drug traceability in an effort to comply with new regulations and combat the rise of fake medicines.
Quintiles, the world's largest CRO, is expecting its revenue to jump as much as 8.5% in 2016 on the heels of a record year.
French contract drug developer Novasep is investing in its U.S. operation, planning to build a new lab in Pennsylvania that will bolster its manufacturing business.
The Michael J. Fox Foundation awarded a grant to Evotec to support the company's work in Parkinson's disease, bankrolling a project meant to clear the way for new therapies.
Catalent Pharma Solutions is building up its clinical supply capabilities in Asia, expanding a Singapore facility as it works on a sizable expansion in Japan.
PRA Health Sciences recruited a healthcare marketing firm with the goal of refining its pitch to potential trial participants and improving recruitment.
CRO giant Icon has expanded its technology portfolio with a system it says can improve patient randomization and clinical supply in adaptive trials.
Parexel lowered its fiscal-year revenue projections by about 2% despite posting modest growth in the last quarter, working through a sizable restructuring program designed to boost profits.
Biotrial, the CRO that ran a Phase I study that proved deadly, said it's working with authorities to piece together what went wrong while trying to move its business forward.